Contineum Therapeutics

The Contineum Therapeutics team will present at two investor conferences next month: the Morgan Stanley 22nd Annual Global Healthcare Conference and the H.C. Wainwright & Co., LLC 26th Annual Global Investment Conference. More details can be found here: https://lnkd.in/gYQ5mjR7 #Biotech #Neuro #MorganStanley2024 #HCW2024

Are you ready for a change? We're hiring! The Contineum Therapeutics team is currently looking for a project manager to support our pre-clinical/clinical programs. More information on this open position and how to apply can be found on our Careers page. https://lnkd.in/geD-4NU5 #biotech #hiring #neuroscience

We're hiring! The Contineum Therapeutics team is currently looking for an experienced Regulatory Affairs professional to join our fast-paced biotechnology Company! More information on this open position and how to apply can be found on our Careers page. https://lnkd.in/gtt9QfFA #biotech #hiring #neuroscience

Today, we announced our 2nd quarter 2024 financial results and corporate update. Read more here: https://lnkd.in/gm6ciWTy #biotech #healthcare

Last week, at the IASP 2024 World Congress on Pain, we presented the effects of our lead asset, PIPE-791, a novel LPA1R antagonist, on brain activation in a nonhuman primate model of peripheral neuropathy. Our findings showed that PIPE-791 significantly reduced activation in brain regions associated with pain perception, suggesting that blocking LPA1 may be a promising approach to treating neuropathic pain. Learn more here: https://lnkd.in/gxMrxqEy #IASP #pain

RRMS is the most common form of multiple sclerosis (MS), characterized by the accumulation of demyelinating lesions in the brain and spinal cord. Our early preclinical data suggest that PIPE-307 is potentially a first-in-class, novel small molecule, selectively targeting the muscarinic type 1 (M1) receptor. We believe PIPE-307 offers a unique and clinically validated approach for treating RRMS and are excited to have our innovative science recognized by the Proceedings of the National Academy of Sciences. Click here to learn more: https://lnkd.in/gsR7F59S

We are pleased to announce that preclinical data on PIPE-307, a potentially first-in-class M1 receptor antagonist in development for patients with relapse-remitting multiple sclerosis (RRMS), were published online in the peer-reviewed journal, Proceedings of the National Academy of Science. Click here to learn more: https://lnkd.in/gsR7F59S

We're hiring! The Contineum Therapeutics team is currently looking for an experienced Accounting Manager to join our fast-paced biotechnology Company! More information on this open position and how to apply can be found on our Careers page. https://bit.ly/3Y56EJT #biotech #hiring #neuroscience

Today, we are participating in the Alexandria Real Estate Equities, Inc. Summit Immunology 2024 biotech event, which aims to stimulate new approaches to the most important issues facing human health. Contineum Therapeutics is pleased to support this local San Diego event and help drive innovation in our industry.                                 #biotech

$CTNM has been added to the #Russell2000Index, which is one of the most widely used benchmarks for small-cap stocks. More information here: https://lnkd.in/g7PDi3rP INDEXRUSSELL: CTNM $CTNM #biotech #neuroscience